Kezar Life Sciences, Inc. (NASDAQ:KZR - Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $7.50, but opened at $7.20. Kezar Life Sciences shares last traded at $7.22, with a volume of 38,681 shares trading hands.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "neutral" rating on shares of Kezar Life Sciences in a research report on Monday, October 14th.
Read Our Latest Research Report on Kezar Life Sciences
Kezar Life Sciences Stock Performance
The company has a debt-to-equity ratio of 0.05, a current ratio of 9.58 and a quick ratio of 9.58. The company has a 50 day simple moving average of $6.88 and a 200-day simple moving average of $6.89. The firm has a market cap of $596.24 million, a PE ratio of -5.85 and a beta of 0.21.
Kezar Life Sciences (NASDAQ:KZR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($2.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.20) by $0.40. As a group, equities research analysts anticipate that Kezar Life Sciences, Inc. will post -1.2 EPS for the current year.
Hedge Funds Weigh In On Kezar Life Sciences
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets boosted its position in Kezar Life Sciences by 35.4% during the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company's stock valued at $247,000 after acquiring an additional 71,543 shares in the last quarter. Fidelis Capital Partners LLC purchased a new stake in Kezar Life Sciences in the first quarter worth $25,000. Marquette Asset Management LLC purchased a new position in Kezar Life Sciences during the first quarter valued at $114,000. Vanguard Group Inc. boosted its holdings in shares of Kezar Life Sciences by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 3,094,224 shares of the company's stock valued at $2,790,000 after buying an additional 30,740 shares in the last quarter. Finally, Acadian Asset Management LLC grew its position in shares of Kezar Life Sciences by 42.5% in the 1st quarter. Acadian Asset Management LLC now owns 1,790,838 shares of the company's stock worth $1,613,000 after buying an additional 534,203 shares during the period. Institutional investors own 67.90% of the company's stock.
Kezar Life Sciences Company Profile
(
Get Free Report)
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.
See Also
Before you consider Kezar Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kezar Life Sciences wasn't on the list.
While Kezar Life Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
